C-myc, not HER-2/neu, can predict recurrence and mortality of patients with node-negative breast cancer

DC FieldValueLanguage
dc.contributor.authorSchlotter, C. M.
dc.contributor.authorVogt, U.
dc.contributor.authorBosse, U.
dc.contributor.authorMersch, Berthold
dc.contributor.authorWaβmann, Katja
dc.date.accessioned2023-07-11T11:28:01Z-
dc.date.available2023-07-11T11:28:01Z-
dc.date.issued2003
dc.identifier.urihttp://osnascholar.ub.uni-osnabrueck.de/handle/unios/70094-
dc.subjectInternal medicine
dc.subjectOncology
dc.subjectBreast cancer
dc.subjectBiology
dc.subjectEcology
dc.subjectUnivariate analysis
dc.subjectTamoxifen
dc.subjectMultivariate analysis
dc.subjectGrading (engineering)
dc.subjectMedicine
dc.subjectCyclophosphamide
dc.subjectChemotherapy
dc.subjectEpirubicin
dc.subjectSurgical oncology
dc.subjectTrastuzumab
dc.subjectCancer
dc.titleC-myc, not HER-2/neu, can predict recurrence and mortality of patients with node-negative breast cancer
dc.typejournal article
dc.identifier.doihttps://doi.org/10.1186/bcr568
dc.description.volume5
dc.description.issue2
dc.identifier.externalhttps://openalex.org/W2124402563
dcterms.oaStatustrue
local.import.sourcefileopenalex_20230710.ris
local.rawaffiliationnull
Show simple item record

Google ScholarTM

Check

Altmetric